How to appeal a Cigna immune globulin (ivig/scig) for pidd denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Cigna-specific note: Sold its Medicaid Advantage book to HCSC in 2023. Express Scripts (PBM) is Cigna-owned. Frequent class-action litigation around mental health parity.

What Cigna's policy requires for immune globulin (ivig/scig) for pidd

Cited policy: Cigna coverage policy — Immune Globulin (IVIG and SCIG)

HyQvia (facilitated SCIG with rHuPH20) covered for PIDD adults and pediatric ages 2-16 per FDA label. Full IVIG-equivalent dose SC every 3-4 weeks. Requires documented PIDD with low IgG + impaired vaccine response.

How Cigna denies immune globulin (ivig/scig) for pidd — and how to counter it

Where Cigna pushes back: 1) Must try conventional SCIG (Hizentra/Cuvitru) first; 2) HyQvia more expensive than weekly SCIG; 3) Hyaluronidase risks (anti-rHuPH20 antibodies).

Counter-arguments that hold up: HyQvia FDA-approved Sep 12, 2014 (adults), expanded to peds 2-16 in 2023 — labeled as direct alternative to IVIG, NOT step after conventional SCIG. Wasserman JACI 2012 pivotal Phase 3 — full IgG dose SC q3-4 wk non-inferior to IVIG. Indications: patient prefers monthly dosing without IV access, IVIG adverse reaction, line burden. Anti-rHuPH20 antibodies clinically silent in long-term safety data (Wasserman + Halozyme post-marketing). Cost-of-care includes infusion-suite + nursing + line maintenance for IVIG.

What Cigna typically denies for immune globulin (ivig/scig) for pidd

Across Cigna's commercial and Medicare books, denials cluster around a small number of patterns. For immune globulin (ivig/scig) for pidd, expect:

• Mental health parity violations
• Step therapy
• Specialty drug prior auth
• OON balance billing disputes

Treatments most often denied in this category

These are the immune globulin (ivig/scig) for pidd treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Privigen (IVIG)
• Gamunex-C (IVIG)
• Octagam (IVIG)
• Gammagard Liquid (IVIG)
• Flebogamma DIF (IVIG)
• Bivigam (IVIG)

How to submit the appeal to Cigna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Cigna cited in the denial.
3. File the appeal through Cigna's portal (members: https://my.cigna.com ; providers: https://cignaforhcp.cigna.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Cigna's prior-authorization criteria by drug: Cigna PA criteria on ApprovalHelp.